How to treat CTD ILD? A comparative slide summarizing ACR/BSR and EULAR treatment guidelines Emphasis on combination of Immunosuppressant and Antifibrotics @RheumNow #APLAR25 https://t.co/gLSht6QKh5

“Listen to the patient, he is telling you the diagnosis”. – Sir William Osler

A framework for treatment stratified approach in CTD-ILD, by Dr Low Hsiu Ling Based on -ILD extent -Risk of progression -Biology: fibrosis/inflammation -Safety -Other manifestations @RheumNow #APLAR25 https://t.co/ma5KugzBHy

‼️More reasons why we should avoid steroids in #lupus patients @RheumNow #APLAR25 https://t.co/a5IeutJ5mi

Why shall we screen all patients with SSc for ILD? Focusing screening strategy on patients « at risk » misses 25% of patients with ILD ILD being the main cause of mortality in SSc @RheumNow #APLAR25 https://t.co/djzCTdZoVb

The overall prevalence of #osteoporosis in SLE is ~33-40% and is due to several factors with GC therapy being one of them. Monitor DXA every 6-12 months (vs. 2 yrs for standard OP) ☝️Screen for GIOP ☝️Treat accordingly - once on GCs & esp w/long-term use @RheumNow #APLAR25 https://t.co/E9FJDHrBUo

Paradigm shift in CTD PAH -Early triple therapy in patients with intermediate and high risk -Sotatercept, a blocker of activin-Smad2/3 signaling have increased survival importantly Data presented by Dr Khanna @RheumNow #APLAR25 https://t.co/Z4yA6DwtOb

An important message from Prof. @XBaraliakos on D2M-axSpA: Re-evaluate your diagnosis & check for comorbids before labelling pts as tx-refractory or difficult-to-manage. consider other causes: FM, other causes of pain @RheumNow #APLAR25 @rheumarhyme @marklagacmd https://t.co/Lo0yShOK0P

Drivers of costs associated with economic costs of RMDs in Asia Pacific -Traditional medicine -Loss of income much higher if worker as opposed to unpaid household labor so high impact of gender roles -Impact of out of pocket health payments due to « catastrophic spendings » in https://t.co/sptwGE7J2V

Prof. Aletaha shares their AutoPiX project - using AI to develop quantitative biomarkers. Something to look forward to since imaging remains an important diagnostic tool in #rheumatology @RheumNow #APLAR25 @rheumarhyme https://t.co/WExT9amazz